Drug intelligence / Profile preview

ECa 233

Development stage: Phase 3
Lead developer: Siam Herbal Innovation
Administration: Oral

Overview

ECa 233 is a standardized extract of Centella asiatica (L.) Urban (Apiaceae) that contains at least 80-85% triterpenoid glycosides with a fixed ratio of madecassoside to asiaticoside (1.50:0.50). It has demonstrated anti-inflammatory, antinociceptive, and analgesic properties in both preclinical and clinical studies, particularly for temporomandibular disorders and trigeminal neuropathic pain.

Other names: Standardized Centella asiatica extract

Targets

P2X3 (P2X purinoceptor 3)Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on ECa 233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECa 233.

Explore the full profile